Soleus Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Soleus Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$43.6M	Buy	131,650 +61,650	+88%	+$21M	1.76%	16
2025 Q4	$27.8M	Buy	70,000 +54,750	+359%	+$24.2M	1.03%	27
2025 Q3	$6.95M	Sell	15,250 -91,500	-86%	-$37.3M	0.35%	53
2025 Q2	$34.8M	Buy	+106,750	New	+$29.5M	2.31%	13
2025 Q1	–	Sell	-76,800	Closed	-$18.1M	–	76
2024 Q4	$18.1M	Buy	76,800 +17,400	+29%	+$4.58M	1.14%	27
2024 Q3	$16.3M	Sell	59,400 -12,300	-17%	-$3.2M	1.27%	29
2024 Q2	$17.4M	Buy	+71,700	New	+$11.3M	1.54%	25
2023 Q4	–	Sell	-3,900	Closed	-$691K	–	76
2023 Q3	$691K	Buy	+3,900	New	+$744K	0.06%	84
2022 Q4	–	Sell	-27,000	Closed	-$5.4M	–	74
2022 Q3	$5.4M	Buy	27,000 +6,900	+34%	+$1.32M	0.73%	40
2022 Q2	$2.93M	Buy	+20,100	New	+$2.85M	0.46%	56

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Soleus Capital Management's ALNY Position: Q1 2026 in Review

Soleus Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 88% in Q1 2026, buying an estimated $21M and bringing the position to 131,650 shares worth $43.6M. The position accounts for 1.76% of the portfolio, ranked #16.

Soleus Capital Management first reported a position in ALNY in Q2 2022 and has held it in 10 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Soleus Capital Management held 131,650 shares of Alnylam Pharmaceuticals worth $43.6M as of Q1 2026.
Soleus Capital Management bought 61,650 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $21M.
Alnylam Pharmaceuticals made up 1.76% of Soleus Capital Management's portfolio in Q1 2026, its #16 holding.
Soleus Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2022 and has held it in 10 quarters since.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.